NCT04831112 is a NA clinical trial of Honey in Necrotizing Fascitis, sponsored by Dow University of Health Sciences.

Who is sponsoring NCT04831112?

NCT04831112 is sponsored by Dow University of Health Sciences.

What drugs are being tested in NCT04831112?

Interventions in NCT04831112: Honey, EUSOL.

What condition does NCT04831112 study?

NCT04831112 studies Necrotizing Fascitis, Wound Infection.

Is NCT04831112 still recruiting?

NCT04831112 is currently completed. Last updated 15 November 2022.

Last reviewed 2022-11-15 · How we verify

NCT04831112

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Compare Effects of Dressing With Honey and EUSOL

Completed NA Last updated 15 November 2022

What this trial tests

NA trial testing Honey in Necrotizing Fascitis in 326 participants. Completed in 31 December 2021.

Timeline

1 March 2020

Primary endpoint
31 December 2021

31 December 2021

Quick facts

Lead sponsor	Dow University of Health Sciences
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	double
Primary purpose	treatment
Enrollment	326
Start date	1 March 2020
Primary completion	31 December 2021
Estimated completion	31 December 2021
Sites	1 location across Pakistan

Drugs / interventions tested

Honey — full drug profile →
EUSOL

Conditions studied

Necrotizing Fascitis — all drugs for Necrotizing Fascitis →
Wound Infection — all drugs for Wound Infection →

Sponsor

Dow University of Health Sciences

Who can join

Adults 18 to 70, any sex, with Necrotizing Fascitis or Wound Infection. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Honey is super saturated solution containing sugar derived from nectar gathered by honeybee. Honey is viscus supersaturated solution mainly composed of sugar and water along with minor constituents such as minerals, vitamins, amino acids, organic acids, flavonoids, and other phenolic compound and aromatic substances. Honey contents according to percentages are fructose 38.6%, glucose 31%, water 17%, lactose 7.2%, larger sugars 4.7% and rest of micronutrients and elemental compounds are 1.5%. Honey enhances wound healing by removing slough and necrotic tissue from wound. It promotes wound healing by increasing angiogenesis, granulation and epithelization. Honey possess antimicrobial activity against bacteria like methicillin resistant staphylococcus aureus, vancomycin resistant Escherichia Coli, pseudomonas aeruginosa, and many other species. It also has activity against some yeast species such as aspergillus and penicillium. Honey used for dressing will be 'Langnese Honey". Langnese honey is raw honey / unprocessed packed as collected, quality and quantity will be same for patients.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

A Comparative Study Between Use of Topical Honey and Edinburgh University's Solution of Lime (EUSOL) Dressing in Necrotizing Fascitis Wounds.
Rai L, Ghufran MA, Samo KA, Mangi MH, et al · · 2023 · cited 1× · PMID 36819392 · DOI 10.7759/cureus.33825

Verify or expand the search:

Other trials of Honey

Trials testing the same drug.

NCT06562257 — Honey as A Wound Care Modality in Treating Deep Neck Space Abscess · NA · recruiting
NCT06456060 — Efficacy of Pure Honey Dressing in Contrast to Alvogyl in the Resolution of Dry Socket · Phase 1 · recruiting
NCT07144969 — Chewing Gum vs Honey in Postoperative Recovery After Ileostomy Reversal: A Study Comparing Their Effects on Bowel Functi · NA · completed
NCT06107231 — WHNRC (Western Human Nutrition Research Center) Honey Study · NA · active not recruiting
NCT05568563 — Comparison of Effectiveness of Pre-cooling With Ethyl Chloride Versus Honey · NA · completed

Other recruiting trials for Necrotizing Fascitis

Currently open trials in the same condition.

NCT06857708 — The Management of Necrotizing Soft Tissue Infection Wounds With Cytal® Wound Matrix and MicroMatrix® · NA · recruiting
NCT07359651 — FATAL-NSTI Study (Factors Associated With In-hospital mortALity in NSTI). · recruiting

Other Dow University of Health Sciences trials

Trials by the same sponsor.

NCT07264829 — This Clinical Trial Aims to Compare the Effectiveness of Two Intra-pulpal Cryotherapy Techniques-Endo-ice and Ice Sticks · NA · not yet recruiting
NCT07526818 — Comparison of Manual and Mechanical Glide Path Techniques for Measuring Root Canal Length Using Standalone Apex Locator · NA · active not recruiting
NCT07433374 — COMPARISON OF THE EFFICIENCY OF MANUAL SINGLE HEADED AND TRIPLE HEADED TOOTHBRUSHES IN REMOVING DENTAL PLAQUE AND USER E · NA · completed
NCT07277621 — Behavioral Interventions to Reduce Social Media Addiction Among School-Going Adolescents in Karachi · NA · completed
NCT07323771 — Improving Oral Health Knowledge and Habits in People With Diabetes Through a Theory Guided WhatsApp Education Program · NA · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04831112 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Dow University of Health Sciences
Last refreshed: 15 November 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04831112.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing